Eval. of Minocycline as a Microglia Inhibitor in Tx of Diabetic Macular Edema

评估。

• 批准号: 9155595
• 负责人: Catherine Cukras
• 金额: $ 6.11万
• 依托单位: NATIONAL EYE INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9155595
• 关键词: Anti-Inflammatory Agents; Anti-inflammatory; Blindness; Caring; Chronic; Data Analyses; Diabetic Retinopathy; Generations; Inflammation; Inflammatory; Lasers; Mediation; Microglia; Minocycline; Neurons; Patients; Pilot Projects; Process; Property; Retina; Retinal; Safety; Site; Tetracyclines; United States; antimicrobial; cellular targeting; diabetic; inhibitor/antagonist; macular edema; prospective

There is accumulating evidence that retinal microglia are indeed associated with diabetic retinopathy. Minocycline is a second-generation tetracycline, which has anti-inflammatory properties that are separate from its anti-microbial properties. The study objective is to investigate the safety and efficacy of minocycline, a microglia inhibitor, in the treatment of diabetic macular edema. This is a prospective, non-randomized, uncontrolled, single group, single center pilot study to investigate the safety and efficacy of minocycline as a microglia inhibitor in patients with DME who have already been treated with standard-of-care laser or who are not amenable to standard-of-care therapy. The study has ended but we continue to analyze the data.

越来越多的证据表明视网膜小胶质细胞确实与糖尿病视网膜病变有关。 米诺环素是第二代四环素，其抗炎特性与其抗微生物特性分开。本研究旨在探讨米诺环素（一种小胶质细胞抑制剂）治疗糖尿病性黄斑水肿的安全性和有效性。 这是一项前瞻性、非随机、非对照、单组、单中心初步研究，旨在研究米诺环素作为小胶质细胞抑制剂在已接受标准治疗激光治疗或不适合标准治疗的DME患者中的安全性和有效性。 研究已经结束，但我们仍在继续分析数据。